Myval transcatheter aortic valve series: An innovation in transcatheter aortic valve implantation technology

Le résumé fourni par la source

The Myval Transcatheter Heart Valve (THV) represents a significant innovation in Transcatheter Aortic Valve Implantation (TAVI) technology, particularly for patients with severe Aortic Stenosis (AS) and complex anatomies. This balloon-expandable, tri-leaflet THV utilizes a nickel-cobalt alloy frame, offering enhanced conformability within the aortic annulus. Structural advancement in the Myval THV series reduces paravalvular leaks and minimizes the need for Permanent Pacemaker Implantation (PPI). Approved for high and intermediate-risk AS patients, Myval has demonstrated consistent safety and efficacy, marked by low rates of procedural complications and mortality in clinical studies. Comparative analyses reveal Myval’s superior hemodynamic performance and reduced vascular complications, attributed to its unique design and range of sizes, including intermediate and extra-large options for anatomies up to 840 mm2 in annulus area. Next-generation developments of Myval also aim to further optimize patient outcomes and procedural safety, promising a valuable expansion of TAVI treatment options. This brief review highlights the design innovations, clinical effectiveness and potential future impact of the Myval THV within the evolving TAVI landscape.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.